Radioactive 'Smart Bomb' targets Hard-to-Treat brain tumors

NCT ID NCT07150806

Recruiting now Disease control Sponsor: Joshua Palmer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called RYZ101 for people with meningioma that has come back or is growing despite standard treatments. RYZ101 is a radioactive substance that targets a protein found on these tumor cells, aiming to kill them while sparing healthy tissue. The trial will check the drug's safety, find the best dose, and see if it can stop the tumor from growing. It is for adults whose tumors show up on a specific PET scan and who have already tried surgery or radiation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracranial meningioma meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MENINGIOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact